Several double blind, prospective trials have demonstrated an antidepressant augmentation efficacy of aripiprazole in depressed patients unresponsive to standard antidepressant therapy. Although aripiprazole is now widely used for this indication, and much is known about its receptor-binding properties, the mechanism of its antidepressant augmentation remains ill-defined. In vivo animal studies and in vitro human studies using cloned dopamine dopamine D2 receptors suggest aripiprazole is a partial dopamine agonist; in this preliminary neuroimaging trial, we hypothesized that aripiprazole 0 s antidepressant augmentation efficacy arises from dopamine partial agonist activity. To test this, we assessed the effects of aripiprazole augmentation on the cerebral utilization of 6-[
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Several double blind, prospective trials have demonstrated an antidepressant augmentation efficacy of aripiprazole in depressed patients unresponsive to standard antidepressant therapy. Although aripiprazole is now widely used for this indication, and much is known about its receptor-binding properties, the mechanism of its antidepressant augmentation remains ill-defined. In vivo animal studies and in vitro human studies using cloned dopamine dopamine D2 receptors suggest aripiprazole is a partial dopamine agonist; in this preliminary neuroimaging trial, we hypothesized that aripiprazole 0 s antidepressant augmentation efficacy arises from dopamine partial agonist activity. To test this, we assessed the effects of aripiprazole augmentation on the cerebral utilization of 6-[
18 F]-fluoro-3,4-dihydroxy-L-phenylalanine (FDOPA) using positron emission tomography (PET). Fourteen depressed patients, who had failed 8 weeks of antidepressant therapy with selective serotonin reuptake inhibitors, underwent FDOPA PET scans before and after aripiprazole augmentation; 11 responded to augmentation. Whole brain, voxel-wise comparisons of pre-and post-aripiprazole scans revealed increased FDOPA trapping in the right medial caudate of augmentation responders. An exploratory analysis of depressive symptoms revealed that responders experienced large improvements only in putatively dopaminergic symptoms of lassitude and inability to feel. These preliminary findings suggest that augmentation of antidepressant response by aripiprazole may be associated with potentiation of dopaminergic activity. & 2014 Elsevier Ireland Ltd. All rights reserved.
Introduction
Three large multi-center trials have reported that the dopamine partial agonist aripiprazole (aripiprazole; Abilify s ) is effective in augmenting the response of patients with major depressive disorder (MDD) to oral antidepressant therapy (Berman et al., 2007; Marcus et al., 2008; Berman et al., 2009) . All three studies, using identical designs, demonstrated that large subset (ranging from 32 to 47%) of patients who failed to respond to eight weeks of monotherapy, selectively responded to aripiprazole augmentation (as compared with blinded placebo). Data from the first two pivotal trials (Berman et al., 2007; Marcus et al., 2008) led to approval by the United States Food and Drug Administration of aripiprazole for use as an antidepressant augmentation agent in major depressive disorder. How aripiprazole brings about this antidepressant potentiation is not known, although it clearly binds with high affinity to dopamine D2 and D3 (D2/3) receptor subtypes (Pae et al., 2008) . In vivo animal studies suggest that aripiprazole has both dopamine D2, presynaptic agonist (Kikuchi et al., 1995; Semba et al., 1995; Momiyama et al., 1996) and antagonist activities (Kikuchi et al., 1995; Inoue et al., 1996) , depending on the assay conditions. The complex pharmacology of aripiprazole may result from variable competition from endogenous dopamine at the same receptors (Burris et al., 2002) . The results of studies in vitro in which endogenous dopamine is removed, more consistently indicate aripiprazole to be inherently a D2 partial agonist (Inoue et al., 1996 (Inoue et al., , 1997 Lawler et al., 1999) .
Whether aripiprazole functions as a partial agonist in humans is still not known with certainty; however, studies using cloned 
